Sold as Ludiomil. Every FDA application for this active ingredient: 1 branded and 10 generic.
As of Nov 16, 2026, FDA lists 11 applications for Maprotiline Hydrochloride (sold as Ludiomil), first approved Dec 1, 1980, with 1 new use approved and 0 published complete response letters.
| Dec 1, 1980 | LudiomilNDA 17543 · New molecular entity | Novartis | 27 | Discontinued |
| Jun 1, 1988 | Maprotiline HydrochlorideANDA 72162 | Heritage Pharma | 8 | Discontinued |
| Jun 1, 1988 | Maprotiline HydrochlorideANDA 72163 | Heritage Pharma | 7 | Discontinued |
| Jun 1, 1988 | Maprotiline HydrochlorideANDA 72164 | Watson Labs | 8 | Discontinued |
| Oct 3, 1988 | Maprotiline HydrochlorideANDA 72285 | Rising | 15 | Discontinued |
| — | Maprotiline HydrochlorideANDA 71943 | Watson Labs | 0 | Discontinued |
| — | Maprotiline HydrochlorideANDA 71944 | Watson Labs | 0 | Discontinued |
| — | Maprotiline HydrochlorideANDA 71945 | Watson Labs | 0 | Discontinued |
| — | Maprotiline HydrochlorideANDA 72129 | Am Therap | 0 | Discontinued |
| — | Maprotiline HydrochlorideANDA 72130 | Am Therap | 0 | Discontinued |
| — | Maprotiline HydrochlorideANDA 72131 | Am Therap | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA